Evidence map›Paper›PMID 42275193›Full record

ReviewThe oncologist2026

Women's health across the reproductive lifespan in women with germline TP53 pathogenic variants: a clinical perspective.

Naama Halpern, Rinat Bernstein-Molho, Yehudit Peerless, Iris Kventsel, Zehavit Frenkel, Yossi Mizrachi, Hagit Shani, Myriam Safrai

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Naama HalpernThe Jusidman Cancer Center, Sheba Medical Center, Ramat Gan 5265601, Israel.
Rinat Bernstein-MolhoThe Jusidman Cancer Center, Sheba Medical Center, Ramat Gan 5265601, Israel.
Yehudit PeerlessThe Jusidman Cancer Center, Sheba Medical Center, Ramat Gan 5265601, Israel.
Iris KventselDepartment of Pediatric Hemato-Oncology, Edmond and Lilly Safra Children's Hospital and Cancer Research Center, Sheba Medical Center, Ramat Gan 5265601, Israel.
Zehavit FrenkelDepartment of Pediatric Hemato-Oncology, Edmond and Lilly Safra Children's Hospital and Cancer Research Center, Sheba Medical Center, Ramat Gan 5265601, Israel.
Yossi MizrachiGray Faculty of Medical and Health Sciences, School of Medicine, Tel-Aviv University, Tel Aviv-Yafo, 6997801, Israel.ORCID 0000-0002-2533-6972
Hagit ShaniPreimplantation Genetic Diagnosis Center, Danek Gertner Institute of Human Genetics, Sheba Medical Center, Ramat Gan 6997801, Israel.
Myriam SafraiGray Faculty of Medical and Health Sciences, School of Medicine, Tel-Aviv University, Tel Aviv-Yafo, 6997801, Israel.ORCID 0000-0002-7979-1655

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Li-Fraumeni syndrome, caused by germline TP53 pathogenic sequence variants (PSVs), is among the most penetrant hereditary cancer syndromes. With broader genetic testing and improved survivorship, more women with TP53 PSVs now seek reproductive and hormonal guidance throughout their lifespan. Yet, no evidence-based framework currently exists to support women's health care in this population. In this review, we searched the available literature and found an absence of data regarding contraception, fertility preservation, pregnancy, and menopause, resulting in inconsistent counseling and both under- and overtreatment. Drawing on analogies from other high-risk cancer syndromes and our multidisciplinary clinical experience, we present interim suggestions centered on shared decision-making, individualized hormonal management, and avoiding unnecessary interventions. These findings underscore the need for prospective studies and international registries to establish evidence-based and equitable women's health care for women with TP53 PSVs.

Indexed as

Germ-Line MutationLi-Fraumeni SyndromeTumor Suppressor Protein p53Women's HealthFemaleFertility PreservationHumansPregnancyTP53 protein, humanTumor Suppressor Protein p53fertility preservationhormonal therapyLi-Fraumeni syndromereproductive healthTP53 pathogenic sequence variantswomen’s health

Identifiers

PMID42275193
PMCPMC13283485

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.